Study in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Major Inclusion Criteria:

• Stable New York Heart Association (NYHA) Class II or III HF diagnosis, evident atleast 6 months prior to enrolment as confirmed by medical history.

• Documented prior objective evidence of heart failure

• Screening ejection fraction ≥50%.

• Adequate bone marrow reserve and organ function at the Screening

• Receiving standard of care heart failure therapy at stable doses for at least 30days prior to Screening.

Major Exclusion Criteria:

• Participant in any other study and has received any other investigational drugwithin 30 days prior to screening or 5-half-lives, whichever is longer, or any otherinvestigational implanted device within 30 days prior to screening, or are takingpart in a nonmedication study which, in the opinion of the Investigator, wouldinterfere with study compliance or outcome assessments.

• Prior diagnosis of hypertrophic cardiomyopathy or a known infiltrative or storagedisorder causing HFpEF and/or cardiac hypertrophy, such as amyloidosis, Fabrydisease, or Noonan syndrome with LV hypertrophy.

• Persistent or permanent atrial fibrillation and is not therapeuticallyanticoagulated for at least the 4 weeks prior to the initial screening visit or isnot adequately rate controlled within 6 months prior to informed consent accordingto investigator discretion.

• Other medical or psychiatric conditions that, in the opinion of the Investigator,would preclude obtaining voluntary consent/assent or would confound the objectivesof the study.